CNS Drugs

Dextromethorphan/ Bupropion: Adis Evaluation

Key points

- An uncompetitive NMDA
 receptor antagonist and sigma 1 receptor agonist
 (dextromethorphan) co formulated with an
 aminoketone and CYP2D6
 inhibitor (which increases
 dextromethorphan
 bioavailability) is being
 developed by Axsome
 Therapeutics, Inc. for use in
 the treatment of CNS
 conditions
- Received its first approval on 18 August 2022 in the USA
- Approved for use in the treatment of MDD in adults

Summary

An oral, fixed-dose combination of dextromethorphan hydrobromide [an uncompetitive N-methyl D-aspartate (NMDA) receptor antagonist and sigma-1 receptor agonist] and the antidepressant bupropion hydrochloride (an aminoketone and CYP2D6 inhibitor that increases dextromethorphan bioavailability) [AUVELITYTM; dextromethorphan/bupropion], is being developed by Axsome Therapeutics, Inc. for the treatment of major depressive disorder (MDD), Alzheimer's disease agitation and smoking cessation.

Dextromethorphan/bupropion was approved in the USA in August 2022 for the treatment of MDD in adults.

This summary represents the opinions of the [author/authors]. For a full list of declarations, including funding and author disclosure statements, and copyright information, please see the full text online. © Springer Nature Switzerland AG 2022.